The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to its new Draft Guidance, “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act [FDA-2019-D-5743]” published in the Federal Register on December 23, 2019.
AMCP Develops 2020 Policy and Advocacy Focus Areas; CMS Issues CY 2021 Advanced Notice for MA Capitation Rates and Part C and Part D Payment Policies – Part II; CMS Issues CY 2021 and 2022 Medicare Advantage and Part D Proposed Rule; CMS Releases New Guidance on Medicaid Waiver Flexibility
A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.
For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.
An analysis published in JMCP found that patients in the North Carolina Medicaid program continued to receive opioids and benzodiazepines concurrently despite known risks. Read the results and recommendations that may benefit this and other Medicaid populations.